Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q1 2025 Earnings Presentation
12 slides from Indivior Pharmaceuticals's earnings presentation, Apr 24, 2025
Slide 1: Q1 2025 Results
Q1 2025 Results April 24, 2025
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
Q1 2025 RESULTS | APRIL 24, 2025 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company’s financial guida
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Q1 2025 Overview
Q1 2025 RESULTS | APRIL 24, 2025 TOTAL NET REVENUE (NR) SUBLOCADE® NR Q1 2025 Overview1 $266m $176m (6)% (2)% OPERATING PROFIT / (LOSS) Non-GAAP OPERATING PROFIT2 $66m $69m (12)% (10)% EARNINGS PER SHARE Non-GAAP EARNINGS PER SHARE2 $0.38 $0.41 (15)% (2)% • Overall results in line with planning assu
Slide 5: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 6: Q1 2025 Financial Highlights
Q1 2025 RESULTS | APRIL 24, 2025 Q1 2025 Financial Highlights OPERATING RESULTS: (REPORTED AND NON-GAAP1) KEY TAKEAWAYS: (VS Q1 2024 UNLESS OTHERWISE INDICATED) $ mil Q1 2025 Q1 2024 Change Total NR decline of 6% (5% at constant FX): Net Revenue (NR): $266 $284 (6)% • U.S. NR down 8%; lower SUBOXONE
Slide 7: Cash and Borrowing Position
Q1 2025 RESULTS | APRIL 24, 2025 Cash and Borrowing Position CASH AND BORROWINGS: KEY TAKEAWAYS: (VS. DECEMBER 31, 2024, UNLESS OTHERWISE INDICATED) ($ in mil.) March 31, 2025 December 31, 2024 Cash & Investments of $400m1 Cash & Cash Equivalents 372 319 • Cash generated by operations and reduced ne
Slide 8: FY 2025 Guidance
Q1 2025 RESULTS | APRIL 24, 2025 FY 2025 Guidance1 GUIDANCE ITEMS: TOP-LINE ASSUMPTIONS: Total NR decline of 17% at the mid-point reflects U.S. SUBOXONE Film (11pp of the decline) and PERSERIS discontinuation (3pp of the decline) Total Net Revenue $955m to $1,025m SUBLOCADE NR2 down 1% at the mid-po
Slide 9: Appendix
Appendix
Slide 10: Key Ongoing Clinical Trials
Q1 2025 Results | April 24, 2025 Key Ongoing Clinical Trials Primary Estimated Trial Population Patients Design Status Endpoints Completion INDV-6001 Moderate to 122 Multiple dose Evaluate PK, safety Recruiting1 Last Patient Last Visit severe Opioid Phase II PK and tolerability of Q4 2025 3-month lo
Slide 11: Financial Reconciliations
Q1 2025 RESULTS | APRIL 24, 2025 Financial Three Months Ended March 31, GAAP selling, general and administrative expenses $ Q1 2025 132 $ Q1 2024 143 Reconciliations1 Adjustments within SG&A Corporate Initiative Transition1 2 0 Acquisition-related costs 2 — 2 Less: Adjustments in selling, general an
Slide 12: INDIVIOR
5 INDIVIOR
Indivior Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix